The estimated Net Worth of Laurent Chardonnet is at least 3.19 百万$ dollars as of 23 May 2023. Mr Chardonnet owns over 5,000 units of Axcella Health Inc stock worth over 193,116$ and over the last 19 years he sold AXLA stock worth over 2,425,188$. In addition, he makes 576,064$ as Consultant at Axcella Health Inc.
Mr has made over 18 trades of the Axcella Health Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of AXLA stock worth 27,500$ on 23 May 2023.
The largest trade he's ever made was exercising 113,776 units of Axcella Health Inc stock on 30 March 2015 worth over 1,889,819$. On average, Mr trades about 13,210 units every 139 days since 2006. As of 23 May 2023 he still owns at least 42,165 units of Axcella Health Inc stock.
You can see the complete history of Mr Chardonnet stock trades at the bottom of the page.
Laurent Chardonnet is the Consultant at Axcella Health Inc.
As the Consultant of Axcella Health Inc, the total compensation of Mr Chardonnet at Axcella Health Inc is 576,064$. There are 5 executives at Axcella Health Inc getting paid more, with Shreeram Aradhye having the highest compensation of 3,911,720$.
Mr Chardonnet is 56, he's been the Consultant of Axcella Health Inc since . There are 7 older and 9 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.
Laurent's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805.
Over the last 6 years, insiders at Axcella Health Inc have traded over 32,393$ worth of Axcella Health Inc stock and bought 29,966,648 units worth 79,278,835$ . The most active insiders traders include Ventures Fund Iv General Pa...、Ventures Fund Iv General Pa...、Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of 3,073,698$. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth 394$.
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
Axcella Health Inc executives and other stock owners filed with the SEC include: